GlassScriptPhysician profile
Kenneth Joseph Brown
NPI 1043279870
$12,202.25
in general payments reported to CMS, 2019-2025
42 companies · $1,969 in 2025
The $1,969 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,253 · 2020: $759 · 2021: $1,337 · 2022: $1,851 · 2023: $1,802 · 2024: $3,230 · 2025: $1,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,967 · Consulting Fee: $1,000 · Education: $34.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,967.18 |
| Consulting Fee | $1,000.00 |
| Education | $34.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,917.17 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,511.81 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,465.34 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $1,219.52 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Anx Robotica Corp | $1,182.10 | 2024 | |
| Pfizer INC. | $551.60 | 2019-2025 | |
| Genzyme Corporation | $404.80 | 2022-2025 | |
| Celgene Corporation | $330.59 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $277.14 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $246.51 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $219.10 | 2021-2024 | Dificid, Recarbrio, Zerbaxa |
| Regeneron Healthcare Solutions, INC. | $212.59 | 2023-2025 | Dupixent |
| Mauna Kea Technologies, INC. | $177.48 | 2021 | |
| Aimmune Therapeutics, INC. | $169.60 | 2024-2025 | Zenpep, Vowst |
| Ferring Pharmaceuticals INC. | $116.68 | 2019-2023 | Rebyota |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $108.18 | 2025 | Rezdiffra |
| Evoke Pharma, INC. | $102.59 | 2022-2024 | Gimoti |
| Celltrion USA INC. | $101.39 | 2024-2025 | Vegzelma, Zymfentra |
| Romark Laboratories, Lc | $92.55 | 2019-2020 | |
| Qol Medical, LLC | $78.92 | 2019-2025 | Sucraid, Sucraid |
| Amgen INC. | $67.21 | 2020-2025 | Avsola, Amjevita, Uplizna |
| Vivus LLC | $63.64 | 2022-2025 | Pancreaze, Qsymia |
| Nestle Healthcare Nutrition INC. | $48.87 | 2022-2023 | |
| Axonics, INC. | $48.69 | 2023 | Axonics |
| Phathom Pharmaceuticals, INC. | $47.43 | 2024 | Voquezna |
| Fresenius Kabi USA, LLC | $45.35 | 2023-2024 | Idacio |
| Novo Nordisk INC | $44.67 | 2025 | |
| Allergan, INC. | $44.59 | 2019-2020 | |
| Medtronic, INC. | $42.70 | 2022-2024 | Gi Genius |
| Redhill Biopharma INC. | $42.58 | 2020-2021 | |
| Braintree Laboratories, INC. | $31.10 | 2022-2025 | Suflave |
| Intercept Pharmaceuticals, INC. | $29.55 | 2022-2023 | Ocaliva |
| Stryker Corporation | $23.02 | 2024 | Pedi-Pom, Neptune |
| Ironwood Pharmaceuticals, INC | $22.24 | 2023 | Linzess |
| Tris Pharma INC | $19.09 | 2019 | |
| Shire North American Group INC | $18.70 | 2019 | |
| Abbott Laboratories | $18.04 | 2019 | |
| Organon LLC | $17.28 | 2023 | Renflexis |
| Alfasigma USA, INC. | $15.81 | 2020 | |
| Endogastric Solutions, INC | $15.42 | 2024 | Esophyx |
| Daiichi Sankyo INC. | $10.61 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$25,178.58 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.